Diadap 5 mg (Tablet)
Unit Price: ৳ 16.00 (3 x 10: ৳ 480.00)
Strip Price: ৳ 160.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dapagliflozin propanediol |
| Company | Opsonin pharma ltd |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- Type 2 diabetes mellitus
Pharmacology
- Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
- Reduces reabsorption of filtered glucose
- Lowers renal threshold for glucose
- Increases urinary glucose excretion
Dosage & Administration
- Recommended starting dose: 5 mg once daily
- Dose can be increased to 10 mg once daily
- Assessment of renal function recommended
- No dose adjustment needed in patients with mild renal impairment
- Safety and efficacy not established in children and adolescents
Interaction
- May enhance diuretic effect of thiazide and loop diuretics
- May increase risk of dehydration and hypotension
- Interacts with insulin and insulin secretagogues
- Potential interactions with antihypertensives, pioglitazone, renal function affecting agents, etc.
Contraindications
- Known hypersensitivity to Dapagliflozin or excipients
- Severe renal impairment
- End-stage renal diseases
- Patients on dialysis
Side Effects
- Hypotension
- Ketoacidosis
- Acute kidney injury
- Impairment in renal function
- Urosepsis and pyelonephritis
- Hypoglycemia with concomitant use with insulin and insulin secretagogues
- Genital mycotic infections
- Increases in low-density lipoprotein cholesterol (LDL-C)
- Nasopharyngitis
- Urinary tract infection
- Bladder cancer
Pregnancy & Lactation
- Pregnancy category C
- Use during pregnancy if benefit justifies potential risk to fetus
- Not recommended during lactation
Precautions & Warnings
- Assessment of volume status and correction of hypovolemia before initiation
- Monitoring for signs and symptoms of hypotension during therapy
- Monitoring of renal function during therapy
- Consideration of lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia
- Not recommended in active bladder cancer
- Caution in patients with a prior history of bladder cancer
- No conclusive evidence of macrovascular risk reduction
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Store below 30°C
- Keep away from light
- Keep away from the reach of children